Discovere-ESO PodcastsImmunotherapy options in the 1st line of treatment of Her2 negative advanced GEJ/Gastric Cancer, the role of CPS value
Immunotherapy options in the 1st line of treatment of Her2 negative advanced GEJ/Gastric Cancer, the role of CPS value

Immunotherapy options in the 1st line of treatment of Her2 negative advanced GEJ/Gastric Cancer, the role of CPS value

Update: 2024-03-20
Share

Description

Expert: Marcelo Porfirio Sunagua Aruquipa, Grupo Oncoclinicas, San Paolo, Brazil

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Immunotherapy options in the 1st line of treatment of Her2 negative advanced GEJ/Gastric Cancer, the role of CPS value

Immunotherapy options in the 1st line of treatment of Her2 negative advanced GEJ/Gastric Cancer, the role of CPS value

ESO - European School of Oncology